The manufacturer of testosterone replacement therapy Testogel (1% transdermal testosterone gel) has confirmed that stock levels of its widely prescribed sachet presentation will return to normal by August 1.
According to Besins Healthcare, the shortfall in global supply of Testogel sachets reported in March has been addressed and it is now “business as usual in Australia”.
“We recognise that many prescribers, pharmacists and patients have been impacted by testosterone supply issues, which were exacerbated by the unexpected withdrawal of a competitor product at the end of last year,” Besins Healthcare Managing Director Geoff Blundell said.
“We have worked diligently to increase supply of Testogel sachets and are pleased to confirm that wholesalers now have ample stock to meet demand.”
Besins Healthcare thanked doctors and pharmacists who had supported patients to transition from Testogel sachets to the Testogel metered-dose pump presentation – which has remained readily available – to ensure continuity of treatment.
“Doctors and patients can now make a decision on which presentation, the pump or the sachets, that they would like to use on an ongoing basis,” Mr Blundell said.
“With ample supplies of the pump and sachets now available, we can ensure men with clinically significant testosterone deficiency receive treatment with Testogel without delay or interruption.”
